We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
AILERON THERAPEUTICS INC NASDAQ false 0001420565 --12-31 0001420565 2024-02-28 2024-02-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...
WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (βAileronβ) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to...
AILERON THERAPEUTICS INC NASDAQ false 0001420565 0001420565 2024-02-09 2024-02-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Aileron Therapeutics, Inc...
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (βAileronβ) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.13 | 19.5164075993 | 5.79 | 7.12 | 5.51 | 63096 | 6.45065269 | CS |
4 | 1.92 | 38.4 | 5 | 7.12 | 4.75 | 33435 | 5.89818615 | CS |
12 | 3.53 | 104.12979351 | 3.39 | 7.12 | 2.87 | 38838 | 4.82208942 | CS |
26 | 5.4 | 355.263157895 | 1.52 | 7.12 | 1.01 | 80246 | 3.60886841 | CS |
52 | 5.57 | 412.592592593 | 1.35 | 7.12 | 1.01 | 50936 | 3.19654877 | CS |
156 | -23.48 | -77.2368421053 | 30.4 | 30.4 | 1.01 | 346956 | 12.44588 | CS |
260 | -27.68 | -80 | 34.6 | 49.4 | 1.01 | 628464 | 22.92037227 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions